ARDELYX, INC. (ARDX): what the price requires

At today's price, ARDELYX, INC. (ARDX) is priced for -2.0% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-19 · Source: https://boothcheck.com/report/ARDX

Headline

FieldValue
TickerARDX
CompanyARDELYX, INC.
Current price$5.11/sh

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisrevenue-multiple
EV / sales paid3.8x
Steady-state operating margin assumed35.5%
Implied growth-2.0%

The company earns no operating profit yet; the inversion runs on the revenue multiple and an assumed steady-state margin.

Solve inputs: computed at a 9.3% cost of capital with 4% terminal growth over a 5-year stage, holding a 35.5% terminal operating margin (88.6% gross margin x the 40% mature-conversion prior); each 1pp of cost of capital moves the implied revenue growth ~5.2pp.

How unusual the bet is: within-range (limited comparison data)

ReferenceValue
vs own history-1.16σ
implied end-window share0%

Valuation X-Ray

The price is justified by relative-multiple and growth-DCF; asset-based land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset8.99x2expensive
Earnings—0—
Relative0.73x2justifies
Growth1.17x2expensive

Families that justify the price: Relative, Growth Families that call it expensive: Asset

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.2%); the inversion above states its own rate.

Per-Model Detail (n=6)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$0.00—noNegative/zero FCF — equity value floored at $0
DCF Exit MultipleGrowth$0.00—noNegative/zero FCF or EBITDA — equity value floored at $0
Relative ValuationRelative$6.960.73xyesP/S fallback (negative EPS): Sector P/S 4.0x × TTM revenue — excluded from consensus
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$0.608.52xyesBook value floor: BV/sh $0.60, ROE negative
Two-Stage Excess ReturnAsset$0.549.46xyesBook value with convergence: BV/sh $0.60, ROE converges to ke
Discounted Future Market CapGrowth$4.791.07xyesRev $0.4B, growth 20% (input: historical growth; tapered), Terminal P/S: 2.4x / 2.9x / 3.5x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth$4.021.27xyesMargin ramp: -14% → 12% over 7yr, rev growth 20% (input: historical growth; tapered)
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative——no—
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative$6.960.73xyesRevenue $0.43B × sector P/S 4.0x
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net cash$34.6m
Interest coverage-4.0x
Share count CAGR (dilution)17.1%
Burning cashyes

Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.

Bullet Takeaways

Bull Case

The most surprising thing about Ardelyx is what the price does not require. A loss-making biotech trading at four times revenue sounds expensive, but inverted, the price assumes roughly flat revenue over the next several years and a long-run operating margin around 35.5%, which is unremarkable for a specialty pharmaceutical with high gross margins. The market is not paying for a breakthrough; it is paying for the existing franchise to hold and eventually convert to profit. That is a much lower bar than the multiple suggests, and IBSRELA is clearing it handily: first-quarter 2026 IBSRELA revenue grew about 58% to $70.1 million. A drug growing nearly 60% does not square with a flat-revenue assumption.

The commercial execution is the bull's strongest evidence. Total product revenue rose 38% to $93.4 million in the quarter, and Ardelyx reaffirmed full-year guidance of $410 to $430 million for IBSRELA and $110 to $120 million for XPHOZAH. IBSRELA addresses a large IBS-C population with a differentiated mechanism, and its growth trajectory is the kind that turns a cash-burning company cash-flow positive as the fixed commercial base gets covered. The company has said it expects to reach cash-flow positivity, and the 10-K frames the path explicitly, targeting "cash flow positivity quarter over quarter and year over year" as the franchise scales.

The XPHOZAH story carries optionality the price is heavily discounting. Ardelyx made the deliberate choice not to file for the Transitional Drug Add-on Payment Adjustment in the Medicare dialysis bundle, prioritizing patient access, and while that disrupted the hyperphosphatemia market through the TDAPA period that ends at the close of 2026, the company believes XPHOZAH is well positioned for 2027. Management has reiterated a long-term expectation for XPHOZAH to reach $750 million in revenue before loss of exclusivity, without assuming restoration of Medicare Part D coverage. Against a drug-manufacturer cohort that includes Axsome, Arcutis, and Kiniksa, the bull case is that IBSRELA's growth alone supports the valuation while XPHOZAH's reimbursement normalization in 2027 is upside the price treats as a question mark.

Bear Case

The sector-specific risk here is reimbursement policy, and it is concentrated in one product. XPHOZAH's commercial fate runs through the Medicare dialysis payment structure, and the company chose not to enter the TDAPA bundle, a decision that protected patient access but disrupted the hyperphosphatemia market through the transition period. The bear's concern is that the 2027 normalization the company is counting on is a forecast about how a government payment program will treat the drug, not a contracted outcome. If the dialysis-bundle economics in 2027 are less favorable than management expects, the $110 to $120 million XPHOZAH guidance and the $750 million long-term target both come under pressure, and there is no commercial lever Ardelyx can pull to override a Medicare payment rule.

The financial structure is the second fault line. Ardelyx is still burning cash, with a negative operating margin, and it has funded its commercial build partly by issuing equity, with the share count rising about 17% in the past year. The 10-K is candid about the dependency: the company "may require additional financing for the foreseeable future as we invest in the growth of IBSRELA and XPHOZAH," and warns that an inability to access capital on acceptable terms could force difficult choices. A company that needs to keep raising money dilutes existing holders, and the bear does not need the drugs to fail; it needs the path to profitability to take longer than the cash and the equity market comfortably support.

The concentration risk ties it together. Ardelyx's entire revenue rests on two products, and the 10-K acknowledges that achieving cash-flow positivity "will be dependent, in part, upon the size" of the addressable patient populations and the company's ability to reach them. Two-product companies have no diversification: a competitive entrant in IBS-C, a label or safety issue, or an adverse reimbursement turn on either drug hits the whole business. The valuation is not stretched, with the methods reading the price as reasonable, so this is not an overvaluation bear. It is a binary-risk bear: a small, two-drug, cash-burning company whose larger product depends on a Medicare policy outcome, where the modest priced-in assumption is achievable only if both the commercial growth and the reimbursement normalization go right.

Valuation

Ardelyx is not yet profitable, so the price is set against revenue, and at about four times sales the implied assumption is strikingly modest: roughly flat revenue and an eventual operating margin near 35.5%, which for a high-gross-margin specialty drug is achievable. The price is not demanding rapid growth; it is asking the existing franchise to hold and convert to profit. That framing matters because IBSRELA is growing nearly 60%, well above the flat assumption, which suggests the price is either skeptical that the growth lasts or is discounting heavily for the XPHOZAH reimbursement uncertainty. Either way, the bar embedded in the price is lower than a four-times-revenue multiple on a loss-maker first implies.

The methods give a thin read because there are no current earnings to anchor on. The relative-multiple lens reaches the price, reading it as reasonable against revenue-based peers, while the asset-value lens flags it as expensive, which is normal for a drug company whose value is its products and pipeline rather than its balance sheet. There is no earnings-power read because the company is loss-making. With the valuation resting mainly on the revenue multiple, the price is best understood as a fair-to-reasonable value on the existing franchise, with the entire debate centered on revenue durability and the XPHOZAH policy path rather than on the multiple being too high or too low.

Solvency is the load-bearing concern and the reason this is a financing story as much as a drug story. Ardelyx holds about $238 million of liquid assets against $204 million of gross debt, a slight net-cash position, but it is burning cash and has said it may need additional financing for the foreseeable future. The share count has grown about 17% a year, real dilution. The right frame for a commercial biotech at this stage is runway to cash-flow positivity, not leverage math: the question is whether IBSRELA's growth covers the fixed commercial base before the company has to raise again on unfavorable terms. Against the drug-manufacturer cohort, Ardelyx's two-product concentration and reimbursement exposure are the reasons the price stays modest, and the valuation reflects a reasonable value on the franchise weighed against the binary risks that a small, focused drugmaker carries.

Catalysts

The first-quarter 2026 print showed strong commercial momentum. Total product revenue rose 38% to $93.4 million, led by IBSRELA up about 58% to $70.1 million, with XPHOZAH at $23.3 million on higher paid prescriptions. Ardelyx reaffirmed full-year 2026 guidance of $410 to $430 million for IBSRELA and $110 to $120 million for XPHOZAH. IBSRELA's growth is the catalyst carrying the story, putting the company within reach of the profitability inflection it has targeted.

The XPHOZAH reimbursement situation is the defining policy catalyst. Ardelyx chose not to file for TDAPA in the Medicare dialysis bundle to preserve patient access, a decision that disrupted the hyperphosphatemia market during the TDAPA period that ends at the close of 2026, after which the company believes XPHOZAH will be well positioned in 2027. Management continues to stand by a long-term expectation for XPHOZAH to reach $750 million before loss of exclusivity, without assuming restoration of Medicare Part D coverage.

The forward watch items are IBSRELA's growth trajectory, the cash-flow inflection, and the 2027 XPHOZAH reimbursement reset. Whether IBSRELA sustains its high-growth pace determines how quickly Ardelyx reaches cash-flow positivity and reduces its reliance on outside financing, the single most important variable for the equity. Separately, how the dialysis-bundle economics treat XPHOZAH once the TDAPA transition ends at the close of 2026 is the event-driven catalyst that will either validate or pressure the larger of the company's two long-term revenue targets.

Peer Cohorts (Per Segment, With Filing Citations)

Ardelyx (single segment) (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Ardelyx Q1 2026 results, 2026 · Ardelyx disclosures, 2026 · Ardelyx FY2025 10-K

View the full interactive ARDX report on boothcheck